Table 3.
Fixed‐Effect Parameter Estimate Equations for Final Model
| Fixed‐Effect Parameter Estimate | Name | Estimate | RSE, % | 95%CI | Coefficient of Variation, % |
|---|---|---|---|---|---|
| θ1 | CL (L/h) | 0.0531 | 1.1 | 0.0519, 0.0543 | |
| θ2 | V1 (L) | 3.04 | 4.1 | 2.8, 3.28 | |
| θ3 | V2 (L) | 8.78 | 3.9 | 8.11, 9.44 | |
| θ4 | V3 (L) | 3.28 | 9.6 | 2.67, 3.9 | |
| θ5 | Q2 (L/h) | 0.288 | 13.2 | 0.213, 0.362 | |
| θ6 | Q3 (L/h) | 2.11 | 10.8 | 1.66, 2.55 | |
| θ7 | CL·ALB | −0.477 | 11.8 | −0.587, −0.367 | |
| θ8 | CL·CLCR | 0.273 | 12.2 | 0.208, 0.338 | |
| θ9 | CL·WT | 0.391 | 13.0 | 0.291, 0.491 | |
| θ10 | V1·ALB | −0.340 | 28.6 | −0.53, −0.149 | |
| θ11 | V1·WT | 0.683 | 11.0 | 0.537, 0.83 | |
| θ12 | V2·AGE | 0.486 | 12.1 | 0.371, 0.601 | |
| θ13 | V2·ALB | −0.413 | 27.2 | −0.633, −0.193 | |
| θ14 | V2·WT | 0.365 | 29.6 | 0.153, 0.577 | |
| θ16 | V3·ALB | −0.551 | 44.4 | −1.03, −0.0714 | |
| θ17 | V3·WT | 0.518 | 44.7 | 0.0644, 0.972 | |
| — | T1/2 (days)a | 8.77 | 1.47 | 8.51, 9.02 | |
| ω1.1 | ω2CL | 0.0489 | 15.5 | 0.034, 0.0638 | 22 |
| ω2.1 | ωCL,V2 | 0.0823 | 22.4 | 0.0462, 0.118 | |
| ω2.2 | ω2V2 | 0.153 | 29.7 | 0.064, 0.242 | 41 |
| ω3.3 | ω2V1 | 0.0566 | 26.6 | 0.0271, 0.0862 | 24 |
| ω4.3 | ω2V1,V3 | 0.111 | 37.5 | 0.0293, 0.192 | |
| ω4.4 | ω2v3 | 0.437 | 19.4 | 0.271, 0.602 | 74 |
| σ1.1 | σ2proportional | 0.0362 | 9.9 | 0.0292, 0.0432 |
ALB, albumin; CI, confidence interval; CL, clearance; CLCR, creatinine clearance; RSE, relative standard error; SE, standard error; V, volume; WT, weight; θ, parameter; ω, interindividual (co)variance estimate; σ, intraindividual variance estimate.
a
T1/2 calculated from 100 000 random samples drawn from mean and covariance of estimated model parameters and is consistent with values from multiple clinical trials.